Adenosine A1 and A3 receptors: Distinct cardioprotection

Drug Development Research

Volumn 52, Issue 1-2, 2001, Pages 366-378

  Liang, Bruce T ^a,c   Stewart, Douglas ^a   Jacobson, Kenneth A ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

A3 receptor; Cardiac myocytes; Cardioprotection; Phospholipase D

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DERIVATIVE;

CONFERENCE PAPER; DRUG MECHANISM; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0035036043     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.1136     Document Type: Conference Paper

References (4)

1. L. Studies in human astroglioma cells. Biochem Biophys Res Commun 241:297-304.
2. 3 receptor involvement. Cardiovasc Res 28:1057-1061.
3. 2B receptor. Mol Pharmacol 52:846-860.
4. 6-(3-Iodobenzyl) adenosine-5′-N- methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80:800-809.